The goal of this clinical trial is to determine if attenuations in cardiac output drive the blunted blood pressure response during cycling exercise following a night of partial sleep deprivation in young healthy adults (%50 females). The secondary outcome is to assess sex differences. The main questions it aims to answer are:
* Do reductions in plasma volume drive reductions in cardiac output and therefore blood pressure during exercise following a night of partial sleep deprivation?
* Do sex differences exist?
Participants will:
* Visit the lab after a night of normal sleep and a night of partial sleep deprivation.
* Keep a daily diary of their sleep and food/beverage intake.
* Perform maximal and submaximal exercise on a cycle ergometer.

开始日期2025-01-01

申办/合作机构

University of Guelph

NCT06119048 / RecruitingN/A

Phe for Me? A Precision Nutrition Clinical Trial of Metabolic, Cardiovascular, and Neurocognitive Responses to Phenylalanine Among Carriers and Non-carriers of PKU

This is a clinical intervention study of PKU carriers (cases) and non-carriers (controls). Upon completing the informed consent process, participants will complete baseline measures of chronic mental health prior to the intervention (PHQ-9, GAD-7, BIS-11). Participants will attend the Human Nutraceutical Research Unit (HNRU) at the University of Guelph, fasted, and first undergo baseline measures of cognition and acute mental health (mood) and provide samples or saliva, urine and dried blood spots to evaluate phenylalanine (Phe), tyrosine (Tyr) and their metabolites (PAH pathway functioning) as well as for genetic testing of the PAH gene. Participants will also complete a brief questionnaire which will include age, sex, ethnicity, income, weight and height (measured using a stadiometer and calibrated weigh scale), and confirmation that participants arrived to the lab fasted (i.e. have only had water to drink and no other foods/ beverages prior to analyses). Blood pressure and heart rate will also be measured at baseline.
Following baseline tests, participants will consume a pure L-Phe supplement dosed at 100 mg/kg mixed with 125 mL of water and 125mL of orange juice. Blood pressure and heart rate will be repeated at 1-hour post-L-Phe consumption. Two-hours postprandial, participants will repeat the cognitive tests and acute mental health (mood) assessment, blood pressure and heart rate measurement and provide follow-up saliva, urine and dried blood spot samples. Participants will also be asked to report any side effects they experienced with the L-Phe consumption.

开始日期2024-06-18

申办/合作机构

University of Guelph

[+2]

NCT06186050 / CompletedN/A

Effects of a High-fat Meal on Exercise-mediated Sympatholysis

The goal of this trial is to examine the effects of a single high-fat meal with or without the co-ingestion of dietary nitrate on exercise-mediated sympatholysis. The main questions it aims to answer are:
1. What are the mechanisms responsible for reduced exercise-mediated sympatholysis following a high-fat meal
2. Can dietary nitrate prevent the declines in exercise-mediated sympatholysis
Participants will be asked to complete three study visits in a randomized order:
1. Low-fat meal
2. High-fat meal
3. High-fat meal plus dietary nitrate
Exercise-mediated sympatholysis will be measured using Doppler ultrasound via a protocol involving rhythmic handgrip exercise and a lower body negative pressure stimulus. Sympatholysis will be assessed before each meal, and at 1, 2, and 3 hours post-prandial.

开始日期2024-01-08

申办/合作机构

University of Guelph

100 项与 University of Guelph 相关的临床结果

登录后查看更多信息

0 项与 University of Guelph 相关的专利（医药）

登录后查看更多信息

40,890

项与 University of Guelph 相关的文献（医药）

2025-01-01·FOOD MICROBIOLOGY

Effectiveness of pasteurization for the inactivation of H5N1 influenza virus in raw whole milk

Article

作者: Nasheri, Neda ; Alkie, Tamiru N ; Pama, Lemarie ; Romero-Barrios, Pablo ; Nfon, Charles ; Hooper-McGrevy, Kathleen ; Alkie, Tamiru N. ; Cutts, Todd ; Alkie, Tamiru ; Berhane, Yohannes ; Krishnan, Jay ; Catford, Angela

Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5Nx viruses continue to cause episodic incursions and have been detected in more than 12 taxonomic orders encompassing more than 80 avian species, terrestrial and marine mammals, including lactating dairy cows. HPAI H5N1 spillover to dairy cattle creates a new interface for human exposure and raises food safety concerns. The presence of H5N1 genetic material in one out of five retail pasteurized milk samples in the USA has prompted the evaluation of the pasteurization processes for the inactivation of influenza viruses. Our study examined whether pasteurization could effectively inactivate HPAI H5N1 spiked into raw whole milk. First, we heated 1 mL of non-homogenized cow milk samples to attain an internal temperature of 63°C or 72°C and spiked with 6.3 log₁₀ EID₅₀ of clade 2.3.4.4b H5N1 virus. Complete inactivation was achieved after incubation of the H5N1 spiked raw milk at 63°C for 30 min. In addition, viral inactivation was observed in seven of eight experimental replicates when treated at 72°C for 15s. In one of the replicates, a 4.44 log₁₀ virus reduction was achieved, which is about 1 log higher than the average viral quantities detected in bulk milk in affected areas. Therefore, we conclude that pasteurization of milk is an effective strategy for mitigation of the risk of human exposure to milk contaminated with H5N1 virus.

2025-01-01·MEAT SCIENCE

Empowering informed choices: How computer vision can assists consumers in making decisions about meat quality

Article

作者: Duarte, Marcio ; Ferreira, Rafael E.P. ; Araujo, Julcimara A. ; Ferreira, Rafael E P ; Valente Junior, Dante T ; Oliveira, Dario A.B. ; Menezes, Guilherme L ; Dorea, Joao R.R. ; Menezes, Guilherme L. ; Oliveira, Dario A B ; Dorea, Joao R R ; Valente Junior, Dante T. ; Araujo, Julcimara A

Consumers often find it challenging to assess meat sensory quality, influenced by tenderness and intramuscular fat (IMF). This study aims to develop a computer vision system (CVS) using smartphone images to classify beef and pork steak tenderness (1), predicting shear force (SF) and IMF content (2), and performing a comparative evaluation between consumer assessments and the method's output (3). The dataset consisted of 924 beef and 514 pork steaks (one image per steak). We trained a deep neural network for image classification and regression. The model achieved an F1-score of 68.1 % in classifying beef as tender. After re-categorizing the dataset into 'tender' and 'tough', the F1-score for identifying tender increased to 76.6 %. For pork loin tenderness, the model achieved an F1-score of 81.4 %. This score slightly improved to 81.5 % after re-categorization into two classes. The regression models for predicting SF and IMF in beef steak achieved an R² value of 0.64 and 0.62, respectively, with a root mean squared prediction error (RMSEP) of 16.9 N and 2.6 %. For pork loin, the neural network predicted SF with an R² value of 0.76 and an RMSEP of 9.15 N, and IMF with an R² value of 0.54 and an RMSEP of 1.22 %. In 1000 paired comparisons, the neural network correctly identified the more tender beef steak in 76.5 % of cases, compared to a 46.7 % accuracy rate for human assessments. These findings suggest that CVS can provide a more objective method for evaluating meat tenderness and IMF before purchase, potentially enhancing consumer satisfaction.

2025-01-01·FOOD CHEMISTRY

Bioaccessibility of avocado polyhydroxylated fatty alcohols

Article

作者: Smith, Richard W. ; Chen, Peter X. ; Rogers, Michael A ; Spagnuolo, Paul A. ; Rogers, Michael A. ; Ahmed, Nawaz ; Spagnuolo, Paul A ; Chen, Peter X ; Smith, Richard W

Avocado-derived polyhydroxylated fatty alcohols (PFAs), such as avocadene and avocadyne, have been recently identified as potent modulators of mitochondrial metabolism which selectively induce leukemia cell death and reverse pathologies associated with diet-induced obesity. However, avocadene and avocadyne bioaccessibility from avocado pulp is not reported; hence, this study aims to investigate if these PFAs are bioaccessible. Dynamic (TNO dynamic intestinal model-1 (TIM-1)) and static in vitro digestion of lyophilized Hass avocado pulp powder shows lipolytic gastrointestinal enzymes led to appreciable bioaccessibility of avocadene (55%) and avocadyne (50%). Furthermore, TIM-1 digestion of a 1:1 ratio of pure avocadene and avocadyne (avocatin B or AvoB) crystals formulated in an oil-in-water microemulsion has on average 15% higher bioaccessibility than the avocado pulp powder demonstrating both dosage forms as potential dietary sources of avocado PFAs. This research provides the impetus for further research on the nutritional significance of dietary long chain fatty alcohols.

项与 University of Guelph 相关的新闻（医药）

2024-09-16

·Business Wire

Investing in Future Discovery: Breast Cancer Canada Awards Research Fellows

LONDON--( BUSINESS WIRE )--Breast Cancer Canada, a national charity dedicated to saving lives through breast cancer research, is proud to announce a significant investment in the future of breast cancer research. The Breast Cancer Canada Translational Research Unit (BCC-TRU) at the London Health Sciences Centre has awarded eight new scholarships and fellowships at Western University for the 2024-2025 academic year, continuing a 25-year tradition of supporting groundbreaking research. This year’s recipients are advancing breast cancer research at London Health Sciences Centre and Western University. Awarded annually through a rigorous review process by Dr. Alison Allan's scientific committee, these scholarships and fellowships honour exceptional scientists, strong mentorship, and groundbreaking research with transformative potential. The recipients are: Zachary Freeman , MSc student in the Department of Epidemiology & Biostatistics Noor Rizvi , MSc student in the Department of Biochemistry Jeri Spilberg , MSc student, Department of Anatomy & Cell Biology Lianghong Chen , PhD student, Department of Computer Science Nitara Fernando , PhD student, Department of Medical Biophysics Jared Wootten , PhD candidate, Department of Epidemiology & Biostatistics George Xie , PhD student, Department of Biochemistry Dr. Samir Fasih , Clinical Research Fellow, Division of Medical Oncology “As Breast Cancer Awareness Month approaches, this announcement serves as a reminder of our ongoing commitment to progress through science,” says Kimberly Carson, CEO of Breast Cancer Canada. “Through the BCC-TRU lab, we are proud to support London Health Sciences and pleased to celebrate the progress and accomplishments made in breast cancer for the last 25 years. The scholarships are not only an investment in breast cancer research, they are also an investment in the bright minds that will shape the future.” Dr. Samir Fasih, Medical Oncology Clinical Research Fellow, London Health Sciences Centre shares, “Receiving the fellowship from Breast Cancer Canada is a powerful opportunity for me to make progress, accelerate breakthroughs in metastatic breast cancer management, and gain invaluable mentorship from Canadian research experts.” The diversity of talent is matched by the breadth of their research focus. Enrolled in six different academic departments at Western University, these scholars are tackling critical aspects of breast cancer, including understanding, prevention, tracking, and treatment of metastatic breast cancer, as well as exploring precision medicine approaches to improve outcomes. Further details about the award recipients and descriptions of their projects can be found on the BCC-TRU website . To learn more about the projects and the people we fund visit Breast Cancer Canada breastcancerprogress.ca . About Dr. Alison Allan Dr. Alison Allan is the director of Breast Cancer Canada’s Translational Research Unit at London Health Sciences Centre and newly appointed Associate Vice-President (Research) at Western University. Dr. Allan is a distinguished oncology scientist known for her impactful research on breast cancer metastasis and new therapies. Dr. Allan has been a part of and holds a BSc in Molecular Biology and Genetics and a PhD in Biomedical Science from the University of Guelph. About Breast Cancer Canada Breast Cancer Canada is a national charity dedicated to saving lives through breast cancer research. With a focus on precision oncology (personalized care), it is the only national breast cancer organization in Canada that has a clear mandate to raise money for research and advocate and educate on the progress of new research evidence. The organization receives no government funding, meaning all research is funded through the generosity of donors. For more information visit, breastcancerprogress.ca .

2024-08-22

·GlobeNewswire-Health Care

Ovarian Cancer Canada announces its annual Walk of Hope to support Canadians facing ovarian cancer

Join or donate to one of the 31 walks across Canada on September 8, visit www.ovariancancerwalkofhope.ca TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Held annually during Ovarian Cancer Awareness Month in September, Ovarian Cancer Canada’s Walk of Hope raises vital funds to power ovarian cancer research, provide education and resources, and fuel advocacy efforts across Canada. Everyone born with ovaries is at risk for ovarian cancer. It is the most fatal women’s cancer, and the reality is that every 5 hours, we lose someone we love to ovarian cancer in Canada. This annual event with thousands of participants across the country has raised more than $33 million since 2002. “Since there is no screening test, the best thing we can do to save lives today is prevent an ovarian cancer diagnosis,” says Tania Vrionis, CEO, Ovarian Cancer Canada. “Money raised from the Walk of Hope goes towards research to detect ovarian cancer earlier, provide better treatment to patients and ultimately eradicate ovarian cancer.” New tool designed to educate women about their risk for ovarian cancer:One way that Ovarian Cancer Canada is preventing ovarian cancer is through its new tool that helps women understand their risk of the disease (launching September 2024). This online questionnaire asks about family history, symptoms and other risk factors and provides recommendations on how to start a conversation with a doctor about preventative action. This tool will educate those at high risk for ovarian cancer and give them the self-advocacy tools they need to stop the disease before it starts. About the Walk of Hope:Ovarian Cancer Canada is the only national charity dedicated to uncovering key discoveries that can change the reality of an ovarian cancer diagnosis. Its Walk of Hope is the only fundraising walk in Canada to direct all attention and money raised towards improving and saving the lives of people with ovarian cancer. Three thousand Canadians are diagnosed with ovarian cancer each year and half of them won’t live to see another five years. It’s time to make ovarian cancer unignorable. Walk with us to demand action and deliver change for women and families affected by this disease. The Ovarian Cancer Canada Walk of Hope is rooted in the community and was founded by Peggy Truscott in 2002. Peggy wanted to create a place where families and individuals living with ovarian cancer could connect with one another, surrounded by a community of support. In May of 2024, Peggy was posthumously awarded the Meritorious Service Cross by the Lieutenant Governor of Ontario, the Honourable Edith Dumont, recognizing her impact and legacy. Participants can register to attend an in-person or virtual Walk. About Ovarian Cancer CanadaOvarian Cancer Canada rejects the notion that ovarian cancer can’t be eradicated. As the only registered Canadian charity solely dedicated to overcoming ovarian cancer, the organization is driving ovarian cancer research faster than ever – changing the landscape of available treatment options. After decades without real change, Ovarian Cancer Canada is making it possible to improve outcomes for patients. Ovarian cancer patients deserve attention. They deserve Canadians’ focus on saving their lives. Towards this goal, Ovarian Cancer Canada is relentless. Follow on Facebook and Instagram @OvarianCancerCanada #WalkofHope For further information: Jack Glassco, Account Executive, Paradigm Public Relations, jglassco@paradigmpr.ca Namrata Peri, Director, Marketing and Communications, Ovarian Cancer Canada, nperi@ovariancanada.org MEDIA ADVISORY/PHOTO-OP: Join Ovarian Cancer Canada’s Walk of Hope on September 8, 2024 Held annually during Ovarian Cancer Awareness Month in September, Ovarian Cancer Canada’s Walk of Hope raises vital funds to power ovarian cancer research, provide education and resources, and fuel advocacy efforts across Canada. Everyone born with ovaries is at risk for ovarian cancer. It is the most fatal women’s cancer, and the reality is that every 5 hours, we lose someone we love to ovarian cancer in Canada. Join us in 31 cities across Canada. For the list of cities, as well as registration information and to donate, please visit ovariancancerwalkofhope.ca. The Ovarian Cancer Canada Walk of Hope is taking place in 31 cities across Canada including: Toronto: Woodbine Park, 1695 Queen St ECalgary: North Glenmore Park, 7305 Crowchild Trail South WestVancouver: Queen Elizabeth Park, 4600 Cambie StBurlington, ON: Spencer Smith Park, 1400 Lakeshore RdMontreal: Angrignon Park, 3400 Boulevard des TrinitairesOttawa: Andrew Haydon Park, 3127 Carling AveEdmonton: Kinsmen Sports Centre, 9100 Walterdale HillWinnipeg: Kildonan Park, Rainbow Stage, 2021 Main StVictoria: Royal Roads University, lower field by boathouse, 2005 Sooke RdGuelph, ON: University of Guelph Arboretum, 200 Arboretum RoadSaskatoon: Gordie Howe Sports Complex, Skating Oval Track and Field Centre 1201 Dudley St WHEN: Sunday September 8, 2024 MEDIA ACCESS: Please proceed to the Registration/Check-in area More information on the event can be found at ovariancancerwalkofhope.ca Contact information: Namrata Peri, nperi@ovariancanada.orgJack Glassco, jglassco@paradigmpr.ca Follow on social media: Facebook/ Instagram: @OvarianCancerCanadaX: @OvarianCanadaHashtag: #WalkofHope

2024-08-21

·GlobeNewswire-Health Care

Rose Hill Announces Addition of Two Senior Advisors to Advisory Team

Burton J. Tabaac MD, FAHA and Rotem Petranker, M.A. Set to Bolster Rose Hill’s Psychedelic Research EffortsWORCESTER, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Rose Hill (or the “Company”), a pioneer in psilocybin research, cultivation and distribution with operations in Jamaica, the United States, and Canada, today announced that Burton J. Tabaac MD, FAHA, and Rotem Petranker, M.A. have both joined the Company’s advisory team. Dr. Tabaac will serve as its Scientific Advisor and Petranker will join the Company as its Research Advisor. Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Tabaac has been at the forefront of innovative neurological treatments. A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, his accolades include being a three-time recipient of The Arnold P. Gold Foundation's Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society. He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac's groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation. He was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens. As the host of The Zero Hour Podcast, Tabaac engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, "Mental Health Meets Psychedelics." "Joining Rose Hill's advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery," said Dr. Tabaac, MD, FAHA. "The company's commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I'm eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine." Rotem Petranker, M.A., is a pioneering figure in psychedelic research and a cognitive neuroscientist specializing in altered states of consciousness. As the founding director of the Canadian Centre for Psychedelic Science in 2018 and co-founder of the Psychedelic Studies Research Program at the University of Toronto in 2019, Petranker has been instrumental in shaping the landscape of psychedelic studies. His expertise spans regulatory compliance, clinical trial design, and the intersection of mindfulness and psychedelics. Petranker's academic journey includes a doctoral candidacy in Psychology, Brain, and Behaviour at McMaster University, where his work focuses on the impact of psychedelics on mental health disorders. Currently, he is leading the world’s first phase II clinical trial investigating the efficacy of microdosing psilocybin in treating Major Depressive Disorder. His research interests extend to the effects of psychedelics on creativity, well-being, and cognitive enhancement, and his work has been published in prestigious journals such as Psychopharmacology and Frontiers in Psychology. "Rose Hill's dedication to producing high-quality, ethically sourced psilocybin is crucial for advancing rigorous scientific research," Rotem Petranker, M.A. stated. "I'm thrilled to contribute my expertise in psychedelic science, particularly in areas such as microdosing and the potential cognitive benefits of psilocybin, to a company that's setting new standards in the industry. This collaboration offers exciting possibilities for expanding our understanding of psychedelics and their therapeutic applications." "The addition of Dr. Tabaac and Mr. Petranker to our advisory team marks a significant milestone in Rose Hill's journey," said Charles Lazarus, CEO of Rose Hill. "Their combined expertise in neurology, psychedelic research, and clinical trial design substantially enhances our capacity to remain at the forefront of psychedelic science. Dr. Tabaac's innovative work in applying psychedelics to neurological recovery, particularly in stroke and brain injury patients, aligns perfectly with our mission to explore new therapeutic frontiers. Meanwhile, Mr. Petranker's groundbreaking research on microdosing and his experience in regulatory compliance will be invaluable as we navigate the complex landscape of psychedelic medicine development. Their involvement not only strengthens our research capabilities but also opens up new avenues for scientific partnerships and innovative projects. This collaboration will undoubtedly accelerate our efforts to develop safe, effective, and ethically produced psilocybin-based solutions, further solidifying Rose Hill's position as a leader in the field of psychedelic medicine." Since its establishment in 2015, Rose Hill has supported multiple clinical research efforts, supplying premium psilocybin biomass to esteemed medical and scientific institutions worldwide. The company achieved a landmark milestone by securing Health Canada's approval for the first legal export of psilocybin from Jamaica to Canada enabling the Company to provide its exclusive, proprietary psilocybin biomass to distinguished Canadian researchers and leading providers of psychedelic-assisted therapies for eligible patients. In addition, Rose Hill has fostered partnerships with institutions such as ACS Labs, the University of Guelph, and the Canadian Centre for Psychedelic Science. These collaborations have not only advanced scientific understanding of psilocybin's therapeutic potential but have also positioned Rose Hill at the forefront of psychedelic research and development. For more information on Rose Hill, visit https://rosehill.life/. About Rose HillRose Hill is a pioneering force in the research, cultivation and distribution of premium psilocybin products and holds the distinction of being the world's inaugural legal exporter of these transformative compounds. With integrated operations spanning Jamaica, the United States, and Canada, the company is committed to setting new industry standards in sustainability, safety, and quality. In the U.S. and Canada, Rose Hill enables cutting-edge research that supports therapeutic applications for psilocybin. In Jamaica, the company produces Consumer Packaged Goods (CPG) and offers transformative psilocybin-assisted retreat experiences. For more information on Rose Hill, visit https://rosehill.life/. Media Contacts: Francesca DeMaurorosehill@kcsa.com

临床2期高管变更

100 项与 University of Guelph 相关的药物交易

登录后查看更多信息

100 项与 University of Guelph 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月19日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Fc3TSR	卵巢癌更多	临床前
rNDV/F3a (University of Guelph)	肿瘤更多	临床前
Cobra toxin antibody (University of Guelph)	蛇咬伤更多	无进展
ETOX-101	假单胞菌感染更多	无进展